Top Markets
#1 Derive Derive +30.93%
#2 Audiera Audiera +14.63%
#3 Cross Cross +11.38%
#4 The Bitcoin Bull The Bitcoin Bull +10.74%
#5 Palladium Network Palladium Network +9.37%
#6 Gama Token Gama Token +9.19%
#7 Biconomy Biconomy +9.00%
#8 Humanity Humanity +8.26%
#9 Geodnet Geodnet +7.98%
#10 Velvet Velvet +7.50%
Coin of the day
Derive Derive
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Dogwood Therapeutics, Inc. Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

DWTX
Classificação em ações #35719
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to... Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Preço da ação
$1.84
Última sincronização: 2026-08-11
Valor de mercado
$3.51M
Variação (1 dia)
0.46%
Variação (1 ano)
-62.71%
País
US
Negociar Dogwood Therapeutics, Inc. (DWTX)

Categoria

Healthcare
Lucros da Dogwood Therapeutics, Inc. (DWTX)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Dogwood Therapeutics, Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Dogwood Therapeutics, Inc. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE